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Abstract
In recent years, it became clear that a better understanding of the interactions among the main elements involved in the
cancer network is necessary for the treatment of cancer and the suppression of cancer growth. In this work we propose
a system of coupled differential equations that model brain tumour under treatment by chemotherapy, which considers
interactions among the glial cells, the glioma, the neurons, and the chemotherapeutic agents. We study the conditions
for the glioma growth to be eliminated, and identify values of the parameters for which the inhibition of the glioma
growth is obtained with a minimal loss of healthy cells.
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1. Introduction
Cells growth is a phenomenon that has been studied
in the fields of mathematics, biology, and physics (Adam
& Bellomo, 1996; Wolpert et al., 2002; Hirt et al., 2014).
Unregulated cells growth may be associated with a wide
group of diseases, where cells become a lump or cause ill-
ness. As a result, several growth models related to tumours
have appeared in the literature (Mecho´n & Condat, 2008;
Aroesty et al., 1973), such as models for the metastasis
(Pinho et al., 2002), the lack of nutrients (Scaleranpdi et
al., 1999), the competition for resources, and the cyto-
toxic activity produced by the immune response (Cattani
& Ciancio, 2008; Wheldon, 1988).
The most common malignant intrinsic primary tumours
of the adult human brain are the gliomas (Inaba et al.,
2011). Gliomas are tumours of the neoplastic glial cells.
They are classified by the World Health Organisation as
oligodendroglioma, astrocytoma, mixed oligoastrocytoma,
and ependymoma (Louis et al., 2007; Goodenberger &
Jenkins, 2012). Glioma causes regional effects by invasion,
compression, and destruction of brain parenchyma, arte-
rial and venous hypoxia (Cuddapah et al., 2014). There is
release and recruitment of cellular mediators which disrupt
normal parenchymal function (Ye & Sontheimer, 1999).
Glioma cells migrate along blood vessels, displacing the
junction among glial cells and blood vessels. This way, the
glioma cells can extract nutrients from the bloodstream.
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Displacements produce disruptions of glial functions, com-
promising adequate delivery of glucose and oxygen to neu-
rons (Cuddapah et al., 2014). Moreover, disruptions of
glial cells affect the neurons, because they are responsible
for delivering nutrients, to provide structural support to
them (Glees, 1955), and to control the biochemical compo-
sitions of the fluid surrounding the neurons. The neurons
are the main responsible for the information processing
from external and internal environments (Otis & Sofronie,
2008; Fieldes, 2006; Shaham, 2005). However, glial cells
are also responsible for the processing of information by
mediating the neural signal. Neurons and their synapses
fail to function without glial cells.
Mathematical modelling of glioma is an extensively ex-
plored area with a large variety of mathematical models
exploring multiple complexities. An approach to mod-
elling glioma is to use differential equations for the total of
cells. In this case, the model ignores the spatial aspects.
Kronik and collaborators (Kronik et al., 2007) proposed a
mathematical model using differential equations for glioma
and the immune system interactions. They incorporated
studies about improved immunotherapy schedules and in-
terventions which can lead to a cure of glioma. There
are models that consider the spatio-temporal evolution,
such as partial differential equations (Harpold & Swan-
son, 2007) and cellular automaton (Alarco´n et al., 2003)
since the evolution of glioma critically depends on spatial
geometry.
In this paper, we propose a mathematical model using
differential equations for the growth of glioma, where the
glioma cells attack the glial cells (Bulstrode et al., 2012).
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Glioma rises from glial cells (Weille, 2014), and glioma
cells never return to be glial cells, resulting in invasion and
destruction of surrounding healthy tissue (Alberts et al.,
1994; Hahn & Weiberg, 2002). In our model, we consider
interactions among glial cells, neurons, glioma cells, and
the chemotherapeutic agent. The novelty of our model was
to introduce the interaction between glial cells and neu-
rons. This interaction is biologically relevant since glial
cells make crucial contributions to the formation, opera-
tion and adaptation of neural cells. Glial cells are essential
for neuronal survival, once their removal causes neuronal
death (Allen & Barres, 2009). With this in mind, the main
features of our model are: (i) treatment will likely preserve
glial cells, (ii) glioma can be eliminated, but not without
also destroying neurons. If the treatment is ceased with-
out the complete elimination of glioma cells, concentration
of glioma cells increases, (iii) there is an optimal duration
for the treatment that reduces significantly the number
of glioma cells by preserving the levels of glial cells and
minimising the impact on the neural populations.
A major impediment to chemotherapy delivery for the
glioma is the blood brain barrier (BBB). The BBB is a
unique physiological structure that regulates the move-
ment of ions, molecules, cells between the brain tissue and
the blood (Gao & Li, 2014). It is necessary to deliver anti-
glioma drugs across the intact BBB to obtain an efficient
treatment of glioma (Srimanee et al., 2014). There are
chemotherapeutic agents that are capable of penetrating
the BBB (Friedman et al., 2000). Yang and collaborators
(Yang et al., 2014) showed blood-brain barrier disruption
through ultrasound for targeted drug delivery. Moreover,
phenotypic heterogeneity of glioma contributes to failure of
chemotherapy (Burrel et al., 2013). Gerlee and Nelander
(Gerlee & Nelander, 2012) studied the impact of pheno-
typic switching on glioma growth and invasion.
2. Brain tumour model
Figure 1 shows a diagram illustrating the many agents,
and their interactions being considered in our model. The
glioma cells only attack the glial cells. Neurons are not
attacked by glioma cells, and they interact with glial cells.
The chemotherapeutic agent behaves as a predator acting
on all cells (Schuette, 2004).
There have been relevant studies that model the time
and space evolution of gliomas. However, as mixed ef-
fect modelling techniques can not be yet applied to spa-
tiotemporal equations (Ribba et al., 2012), then we have
consider differential equations aiming to yield a simplified
description of the biological process according to schematic
representation which it is showed in Figure 1. Our math-
ematical model describes the cells concentration, and the
concentration of chemotherapeutic agent. Due to mixed
effects we leave out spatial considerations, and our model
is a new approach to modelling the dynamic evolution of
the cells concentration in a brain tumour with glia-neuron
interactions.
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Figure 1: Schematic representation of the agents (in gray coloured
boxes), and their interactions (links) considered in our model.
Our model is described by
dG(t)
dt
= Ω1G(t)
(
1−
G(t)
K
)
−Ψ1G(t)C(t)
−
P1G(t)Q(t)
A1 +G(t)
, (1)
dC(t)
dt
= Ω2C(t)
(
1−
C(t)
K
)
−Ψ2G(t)C(t)
−
P2C(t)Q(t)
A2 + C(t)
, (2)
dN(t)
dt
= ψG˙(t)H(−G˙)N(t)−
P3N(t)Q(t)
A3 +N(t)
, (3)
dQ(t)
dt
= Φ− ζQ(t), (4)
whereG represents the glial cells concentration (in kg/m3),
C represents the glioma cells concentration (in kg/m3),
N the neurons cells concentration (in kg/m3), Q is the
concentration of the chemotherapeutic agent (in mg/m2),
and H(x) is the Heaviside function, defined as
H(x) =


0, x < 0,
1
2 , x = 0,
1, x > 0.
(5)
Table 1 shows the parameters that we consider. In Eqs.
(1) and (2), the first term is the logistic growth, the second
term is the interaction between glial and glioma cells. This
term is due to microglia cells, that are a type of glia, which
act creating on active immune defense. They have the
ability to generate innate and adaptive immune responses
(Yang et al., 2010). The glioma is attacked by microglia,
and as a result the glioma cells discharge immune suppres-
sive factor to defend it by paralysing the immune effector
mechanism (Ghosh & Chaudhuri, 2010). The last term of
the Eqs. (1) and (2) is the effect of the chemotherapeutic
agent. We consider that the chemotherapy acts killing the
cells with different intensities according to the Holling type
2 killing functions. Holling (Holling, 1965) suggested kinds
of functional responses to model phenomena of predation.
Holling found that the predator has a Holling 2 functional
2
response by taking into account the time a predator takes
to handle the prey it has captured (Pei et al., 2005). The
first term of Eq. (3) is related with the decrease in the neu-
ral population due to glial cells death, and the second term
is the interaction with the chemotherapeutic agent. Equa-
tion (4) describes the dynamics of the chemotherapeutic
agent, presenting an exponential decay in concentration.
The agent rate ζ in this equation is associated with the
decrease of chemotherapy that is delivered to the cells. As
a result of the washout, and mainly by the blood brain
barrier which prevents entry of chemotherapeutic agents
into the brain.
Table 1: Description of the parameters according to literature.
Description Parameter Values Comment
Proliferation Ω1 for
GCs
0.0068 day−1 Ω1 < Ω2
(Pinho et al.,
2013)
rate Ω2 for
CCs
0.012 day−1 Reference
(Spratt &
Spratt, 1964)
Loss influ-
ences
ψ for N
due GCs
0− 0.02 Reference
(Pinho et al.,
2013)
Interaction
coefficients
P1 for
GCs
2.4 ×10−5
m2(mg·
day)−1
Reference
(Pinho et al.,
2013)
P2 for
CCs
2.4 ×10−2
m2(mg·
day)−1
P2 > P1
(Rzeski et al.,
2004)
P3 for N 2.4 × 10−5
m2(mg·
day)−1
P3 = P1
Chemotherapy Φ for in-
fusion
0 − 150 mg
(m2· day)−1
Daily doses
(Stupp et al.,
2005)
agent rate ζ 0.2 day−1 Reference
(Borges et al.,
2014; Said et
al., 2007)
Holling type
2
A1, A2, A3 510 A1 = A2 =
A3 = Ki
Competition
coefficients
Ψ1 be-
tween
GCs and
CCs
3.6 × 10−5
day−1
Cancer hy-
pothesis
(Pinho et al.,
2013)
Ψ2 be-
tween
CCs and
GCs
3.6 × 10−6
day−1
Ψ2 < Ψ1
Carrying ca-
pacity
K1,K2,K3 510 kg/m3 Reference
(Azevedo et
al., 2009)
Glial cells are required, both in vitro and in vivo, for
the survival of the neurons with which they interact. Re-
moval of glial cells results in neuronal death, unless spe-
cific survival factors are added (Meyer-Franke et al, 1995).
There are studies showing that neuron death in the ab-
sence of glial is best fit by an exponential decay. Clarke
and collaborators (Clarke et al., 2000) verified exponential
decay in the kinetics of neuronal death in 12 models of
photo-receptor degeneration, hippocampal neurons under-
going excitotoxic cell death, a mouse model of cerebellar
degeneration, and Parkinson’s and Huntington’s diseases.
Therefore, our main contribution in this work is to model
the dependence of neurons on the glial cells, described by
the term ψG˙(t)H(−G˙)N(t), in Eq. (3). This term rep-
resents an exponentially decaying function of N(t), given
by N(t) = exp(ΛG(t)), where Λ = ψH(.). When the glial
concentration decreases, G˙ becomes negative, making this
term to contribute negatively to N(t), leading to a de-
crease in the neuron concentration. Whereas, the term
is null if the rate of glial concentration, G˙, is null or posi-
tive. Therefore, a decrease in the glial concentration causes
death of neurons, whereas an increase does not contribute
to a change in the neural population.
Recent years have seen a surge in studies about glial-
neuronal interaction, providing insights into the role of
glial cells in neuronal function (Tiwari et al., 2014; Nakae
et al., 2014). With this in mind, we consider in this
work the glial-neuronal interaction due to the fact that the
glioma has the origin of glial cells which are active partic-
ipants in nervous system. We believe that our model is a
first step towards advanced modeling techniques treating
brain tumour considering glia-neuronal interactions, which
in turn may have relevant impact both on tumour research
and on clinical practice.
Introducing the normalised variables
g =
G
K1
, c =
C
K2
, n =
N
K3
, (6)
where Ki is the carrying capacity of the glial, glioma, and
neural cells, respectively, we obtain the normalised math-
ematical model
dg(t)
dt
= Ω1g(t)(1− g(t))− β1g(t)c(t)
−
p1g(t)Q(t)
a1 + g(t)
,
dc(t)
dt
= Ω2c(t)(1− c(t))− β2g(t)c(t)
−
p2c(t)Q(t)
a2 + c(t)
,
dn(t)
dt
= αg˙(t)H(−g˙)n(t)−
p3n(t)Q(t)
a3 + n(t)
,
dQ(t)
dt
= Φ− ζQ(t), (7)
with
β1 = Ψ1K2, β2 = Ψ2K1, α = ψK1,
a1 =
A1
K1
, a2 =
A2
K2
, a3 =
A3
K3
,
p1 =
P1
K1
, p2 =
P2
K2
, p3 =
P3
K3
, (8)
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where Table 2 exhibits the values of the normalised pa-
rameters. The normalised model provides variables that
reflect the relative density of a population of cells with
respect to the mass density of the brain approximately
K = 510 kg/m3. For example, n = 0.3 would mean 30%
of total number of neurons that an individual could have.
This normalised model allows to make comparative anal-
ysis when the model is used to simulate glioma grown in
different individuals. A healthy individual, in this nor-
malised model, would be described by the state variables
g = 1, c = 0, and n = 1.
Table 2: Values of the normalised parameters.
Parameters Values
β1 1.8× 10
−2 day−1
β2 1.8× 10
−3 day−1
α 0.0− 10.0
a1 = a2 = a3 1.0
p1 = p3 4.7× 10
−8 m2(mg· day)−1
p2 4.7× 10
−5 m2(mg· day)−1
Firstly, we check the behaviour of the glioma without
the infusion of a chemotherapeutic agent. Since there is
no treatment the glioma cells kill the glial cells (Fig. 2a),
while the glioma cells grow (Fig. 2b). Without the glial
support, the neurons die (Fig. 2c). For t = 500 there
are around 34% of glial cells, and approximately 27% of
neurons. Due to the logistic growth of the glial cells, they
resist longer than the neurons from the attack of glioma.
As a result, without chemotherapy (Fig. 2d) the glioma
cells are going to kill all the cells (Figs. 2a, and c).
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Figure 2: Temporal evolution of the concentration of (a) glial cells,
(b) glioma cells, (c) neurons and (d) chemotherapeutic agent (Φ = 0).
We consider g(0) = 0.99, c(0) = 0.01, n(0) = 0.99, Q(0) = 0.0, and
parameters according to Table 2.
Then, we use the infusion of a chemotherapeutic agent
in order to suppress the glioma growth. Figure 3 shows a
case where our model exhibits a suppressed state. In the
interval 0 < t < 50 the glial cells concentration decreases
(Fig. 3a) due to the attack of glioma and the presence of
the chemotherapeutic agent, as well as, for t > 50 we have
c < 0.005 (Fig. 3b). Figure 3(c) exhibits a fast decay of the
neurons due to the effect of the chemotherapeutic agent on
the neuron population and the decay of glial cells. Glial
cells recover their normal concentration level which slows
down the decay of neuron cells. If the chemotherapeutic
agent is not suspended it will eventually kill all neurons,
since in our model we are not considering the neuroge-
nesis. The chemotherapeutics induce neurons death is a
side effect known as neurotoxicity. Lomustine, cisplatin,
topotecan, and vincristine are antitumour agents that in-
duce cell death. Antje Wick and collaborators (Wick et
al., 2004, 2009) analysed the effect of these drugs on the
neurons. They verified which drugs lead to cell death in
cerebellar granule neurons in a concentration dependent
manner.
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Figure 3: Temporal evolution of the concentration of (a) glial cells,
(b) glioma cells, (c) neurons and (d) chemotherapy, continuous treat-
ment Φ = 100. We consider g(0) = 0.99, c(0) = 0.01, n(0) = 0.99,
Q(0) = 0.0 and parameters according to Table 2.
3. Local stability
The study of the local stability is important to verify
if the suppression of glioma is stable or unstable, or to un-
derstand whether a non desired state is stable. The model
has some equilibria points E(g, c, n,Q). They are solution
of the system g˙(t) = 0, c˙(t) = 0, n˙(t) = 0, Q˙(t) = 0. We
consider the equilibria points physiologically feasible.
Now, we analyse the local stability for an undesirable
equilibrium, where this equilibrium is E0(0, 0, 0,Φζ
−1).
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The eigenvalues of the Jacobian matrix are
λ
(0)
1 = Ω1 −
p1Φ
ζa1
, (9)
λ
(0)
2 = Ω2 −
p2Φ
ζa2
, (10)
λ
(0)
3 = −
p3Φ
ζa3
, (11)
λ
(0)
4 = −ζ. (12)
Through the sign of the real part of each eigenvalue we can
check the stability of the equilibrium. In a hyperbolic equi-
librium, if the real part of each eigenvalue is strictly nega-
tive, then the equilibrium is locally asymptotically stable.
If positive, then the equilibrium is unstable. In order to
ensure the stability of E0(0, 0, 0,Φζ
−1) it is necessary that
Φ >
Ω1a1ζ
p1
, (13)
and
Φ >
Ω2a2ζ
p2
, (14)
where these results are obtained through λ
(0)
1 < 0, and
λ
(0)
2 < 0. The values of the normalised parameters are
positive, then the eigenvalues λ
(0)
3 , and λ
(0)
4 are negative.
We consider a1 = a2 = 1, Ω1 = 0.0068, Ω2 = 0.012, p1 =
4.7 × 10−8, p2 = 4.7 × 10
−5, and ζ = 0.2 (table 1). With
these values we obtain that E0 is linearly asymptotically
stable for Φ > 28936.17. In other words, if Φ > 28936.17
the chemotherapeutic agent kills all cells, they will never
recover. Stability of the non-cells state is however granted
for a very large atypical value of the infusion rate Φ.
We also consider the equilibrium E1(g, 0, n,Q), rep-
resenting the complete elimination of glioma cells in the
normalised model, but preserving glial and neuron cells.
This equilibrium is obtained by the solution of
Ω1g(1− g)−
p1gQ
a1 + g
= 0,
−
p3nQ
a3 + n
= 0,
Φ− ζQ = 0, (15)
where we obtain n = 0 and Q = Φζ−1. Thus, the equilib-
rium E1(g, 0, n,Q) is given by E1(g, 0, 0,Φζ
−1), meaning
that all neurons are also eliminated.
The first equation of (15) can be rewritten as
g2 + (a1 − 1)g − a1 +
p1Φ
Ω1ζ
= 0, (16)
with solution
g =
1
2
{
1− a1 ± [(a1 − 1)
2
+ 4(a1
−p1Φ/Ω1ζ)]
1/2
}
. (17)
In this way, we verify that g has a null solution when
p1Φ/Ω1ζ = a1, and a real, positive and not null solution
when p1Φ/Ω1ζ < a1. Using the parameters of Table 2,
g has a real, positive and non null solution when Φ <
28936.17.
Calculating a lower band for the value of Φ for which
the equilibrium E1(g, 0, 0,Φζ
−1) is stable, we determine
the stability of this equilibrium. The eigenvalues of the
Jacobian matrix are
λ
(1)
1 = Ω1(1− 2g)−
p1a1Φ
ζ(a1 + g)2
, (18)
λ
(1)
2 = Ω2 − β2g −
p2Φ
ζa2
, (19)
λ
(1)
3 = −
p3Φ
ζa3
, (20)
λ
(1)
4 = −ζ. (21)
In order to ensure the stability of E1(g, 0, 0,Φζ
−1) it is
necessary
p1Φζ
−1 >
Ω1(1− 2g)(a1 − g)
2
a1
, (22)
and
p2Φζ
−1 > a2(Ω2 − β2g), (23)
where these results are obtained through λ
(1)
1 < 0, and
λ
(1)
2 < 0. The values of the dimensionless parameters are
positives, then the eigenvalues λ
(1)
3 , and λ
(1)
4 are negatives.
For a1 = 1.0 (Table 2) Eq. (22) is satisfied for all g ≥
0.5. Considering a2 = 1.0, Ω2 = 0.012, p2 = 4.7 × 10
−5,
ζ = 0.2, and β2 = 1.8 × 10
−3 (Table 2) in Eq. (23) we
have Φ > 51.064−7.660g. As a result, for E1(g, 0, 0,Φζ
−1)
the system presents an asymptotically stable equilibrium
for Φ > 43.189. Therefore, for realistic values of the in-
fusion rate 43.189 < Φ < 28979.255, we should expect
that glioma can be eliminated, i. e., c ≤ 10−11. Do-
ing similar analyses in the non-normalised system, we ob-
serve that the equilibrium E(g¯, 0, n¯, Q¯) is also stable for
43.189 < Φ < 28979.255.
We construct the parameter space shown in Fig. 4 to
obtain a picture of the stability according to parameters
related with the chemotherapy. We can observe three re-
gions. Region I represent parameter which the glioma cells
kill the glial cells and neurons, region II represents param-
eters for which the equilibrium E1(g, 0, 0,Φζ
−1) is locally
stable, and in region III represents parameters for which
the equilibrium E0(0, 0, 0,Φζ
−1) is locally stable. The re-
gion II shows that glioma can be eliminated without the
elimination of the glial cells. However, the longer the du-
ration of treatment, the larger the decrease in the neural
population. It is therefore vital to understand what are
the optimal parameters for which c ≤ 10−11 is achieved in
the shortest time.
A strongly desired equilibrium is E2(g, 0, n, 0). In this
case we have g = 1 and n has a constant value. The
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Figure 4: (Colour online) Parameter space ζ versus Φ: in the region
I the glioma cells kill the glial cells and neurons, the region II shows
which the equilibrium E1(g, 0, 0,Φζ−1) is locally stable, and in the
region III the equilibrium E0(0, 0, 0,Φζ−1) is locally stable.
eigenvalues are λ1 = −Ω1, λ2 = Ω2 − β2, λ3 = 0, and
λ4 = −ζ. Using the parameters given in Table 2 we obtain
negative values for λ1 and λ4, λ2 has a positive value, and
λ3 presents a null value. This equilibrium is an unstable
saddle point. Then, if treatment is ceased without the
complete elimination of the glioma cells (c = 0), the glioma
concentration in our model increases.
4. Glioma elimination
Here, we study the performance of our model to under-
stand what are the conditions such that glioma concentra-
tion in the normalised model reaches levels related to no
glioma (c ≤ 10−11), while glial and neuron cells concen-
tration are kept high.
Figure 3 shows a case for eliminated glioma. However,
the neurons concentration is decreased by 1.5% when the
tumour has significantly decreased. In this case, glioma
is eliminated, but a significant population of neurons are
damaged. For this reason we optimise the values of the
chemotherapeutic agents in order not only to minimise the
impact on neurons but also to maximise the effect of the
drug on glioma cells. Our aim is to understand how the
neuron population is when c ≤ 10−11. The therapeutic
implication for neurons is shown in Figure 5, the neuron
concentration (colour bar) when c ≤ 10−11, as a function
of the parameters α and Φ. In this case, we consider a
chemotherapy delivered continuously. The region of α and
Φ values responsible for the reduction of approximately 2%
in the neuron concentration (yellow online) is 0.96 ≤ n ≤
0.98, while the region 0.80 ≤ n ≤ 0.84 (dark blue online)
presents approximately a reduction of 17%. This region of
parameters causes a large rate of death of the glias (large
g˙). The chemotherapy rate Φ also contributes to this low
level of n.
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Figure 5: (Colour online) Neuron concentration as a function of α
versus Φ, where g(0) = 0.99, c(0) = 0.01, n(0) = 0.99, and Q(0) =
0.0. The colour bar represents the value of the neuron concentration,
n, after a successful chemotherapy.
Since that glial cells provide support functions for the
neurons, we also analyse the concentration of the glial cells
with the chemotherapy treatment. For the parameter val-
ues showed in Fig. 5, the percentage of glial cells remains
larger than 95%. Equations (7) show that the glial cells
equation does not depend on the parameter α, but it de-
pends on the parameter Φ due to Q. When Φ increases, we
verify that c decreases. However, there is not a significant
variation in g due to the lifetime glioma τ according to
the chemotherapy agent rate. In other words, increasing
the value of Φ the lifetime of glioma quickly decreases, and
in this time interval the glial cells concentration does not
have a significant alteration, due to the fact that the glial
cells are able to recover to their initial state.
Figure 6 shows the time τ to achieve suppression of
glioma as a function of Φ. There is a power-law rela-
tion of the type τ ∝ Φσ, with σ = −12.36 for Φ ≤ 60
mg(m2·day)−1 and σ = −1.41 for Φ ≥ 60 mg(m2·day)−1.
This power-law shows that a significant decrease in τ hap-
pens if Φ ≤ 60 mg(m2·day)−1, whereas little modification
in τ happens if Φ > 60 mg(m2·day)−1. Therefore, the op-
timal way of reducing the time of treatment by using the
minimal amount of Φ is obtained if Φ ≈ 60 mg(m2·day)−1.
Looking at Fig. 5, neurons will also be significantly pre-
served if α ≤ 2. The same scalings are obtained if another
α if considered. The chemotherapeutic agent which pro-
vides the quickest is Φ ≤ 60 mg(m2·day)−1. Treatment
will cause less impact on neural population if the individ-
ual being treated (characterises by a particular α) is pro-
vided with an infusion rate Φ such that the point (Φ,α)
falls in the yellow region in Fig. 5.
Often chemotherapy treatments are delivered in cycles,
where drugs are repeatedly applied for a short time. In the
case of glioma and temozolomide, after radiation therapy,
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Figure 6: τ versus Φ, and the same values as Figure 5. The
slope for Φ ≤ 60 mg(m2·day)−1 is about −12.36, and for Φ ≥ 60
mg(m2·day)−1 the slope is about −1.41.
the drug is delivered 5 days on, and 23 days off. There
have been clinical experiences with temozolomide consid-
ering pulsed chemotherapy in patients with glioma (Fried-
man et al., 2000; Pace et al., 2003). The patients received
radiotherapy before the chemotherapy. It was verified that
temozolomide chemotherapy was a valid option.
Figure 7(a) shows the drug injection pattern for pulsed
chemotherapy. We consider 5 days on with Φ = 400
mg(m2·day)−1, and 23 days off. Figures (b), (c), and (d)
exhibit the temporal evolution of the concentration of glial
cells, glioma cells, and neurons, respectively. There is not
a relevant decrease in the concentration of glial cells (Fig.
7b), but the concentration of glioma cells are going to a
suppressed state (Fig. 7c). Whereas, the concentration of
neuron decreases around only slightly.
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Figure 7: Temporal evolution of the (a) chemotherapy infusion, con-
centration of (b) glial cells, (c) glioma cells, and (d) neurons.
5. Conclusions
We proposed a mathematical model for the evolution
of a brain tumour under the attack of chemotherapeutic
agents. Our model describes the interactions among glial
cells, neurons, and glioma, with a chemotherapy to sup-
press the brain tumour. The novelty in this model is the
glial effect on the neurons.
We studied some aspects of the dynamics of glioma
growth, as well as, we analysed its suppression and elimi-
nation varying parameters of the system. The main target
of treatment is the decrease in the number of glioma cells.
A successful chemotherapy eliminates all the glioma cells
minimising the neurons and glial cells injury. Through lo-
cal stability we found a range of values for the infusion
rate (43.189 < Φ < 28979.255) that allows for the elim-
ination of glioma, as well as, the glioma will not return.
As a matter of fact the temozolomide is a chemothera-
peutic drug used for brain tumour, where the infusion
rate is 75 < Φ < 200 (mg(m2· day)−1) (Wick et al.,
2009). According to our model the rate would kill all
the glioma cells, and in addition it would preserve high
levels of neural population. The range of the values for
the infusion rate is clinically relevant because it reveals
the effectiveness of the treatment strategies by adminis-
tration of chemotherapeutic drugs. Brock and collabo-
rators (Brock et al., 1998) used an extended continuous
oral schedule of temozolomide against gliomas. They ver-
ified which patients with recurrent glioma were the main
group in that tumour responses were seen. Clinical stud-
ies conducted by the Cancer Research Campaign (London,
United Kingdom) demonstrated which temozolomide has
important efficacy an acceptable safety profile in the treat-
ment of patients with glioma (Friedman et al., 2000). New
strategies have been developed aiming health benefits of
patients, that is the elimination of glioma cells (Minniti
et al., 2009). Regardless whether doctors will use the op-
timal rates obtained from our model, our work can help
doctors to access the risks of a treatment on an individual
basis. For example, Figure 5 shows that depending on the
value of α (a parameter that depends on the individual)
the range of vales for the infusion rate can be larger as
smaller for an optimal application.
We realised numerical simulations and obtained val-
ues of the infusion of chemotherapeutic agents in that the
glioma growth is eliminated within the shortest time. We
considered a continuous infusion throughout the entire pe-
riod of simulation. However, Φ can be time dependent to
simulate pulsed chemotherapy.
Our main result was to show that chemotherapy can be
applied mitigating the side effects of drugs on the neurons
death, if the appropriated rate is used. Mechanisms of
chemotherapy-induced neurotoxicicty have not been com-
pletely elucidated. Wick and collaborators (Wick et al.,
2004) analysed the effects of four chemotherapeutic drugs
(lomustine, cisplatin, topotecan, and vincristine) on neu-
rons and glias derived from rats. They observed neuron
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death in a concentration-dependent manner. Gong and
collaborators (Gong et al., 2011) also analysed the neuro-
toxicity due to chemotherapy against glioma. They con-
cluded that newer chemotherapy agents (proteasome in-
hibitor bortezomib, and epidermal growth factor recep-
tor tyrosine kinase inhibitor erlotinib) are effective against
glioma cells, producing minimal effects on neurons. Older
drugs (temozolomide, and cisplatin) are more toxic for
neurons than for glioma cells. With this in mind, it is
possible to obtain an appropriate infusion rate if we have
the time evolution of the neuron concentration when a
chemotherapy agent is applied in the brain.
Our model suggests that the death of one glioma may
occur after 20 weeks. On the other hand, by 10 weeks
the model presents a decrease about 70% in the concen-
tration of glioma cells. For instance, the temozolomide has
good penetration into brain, and Oshiro and collaborators
reported the clinical efficacy of temozolomide in patients
with glioma (Oshiro et al., 2009). They observed the re-
duction of ≥ 50% in tumour size for ≥ 4 weeks of the 40%
of patients. The effect depends on the infusion rate that
is associated with the drugs and methods of treatments.
Moreover, the dose rate also depends on the side effects of
chemotherapy on the body, due to the fact that different
drugs cause different effects (Brock et al., 1998).
We believe that our model, which consider the interac-
tion between neuron and glia, constitutes an important
step toward developing strategies for glioma treatment.
The understanding of tumour growth dynamics may help
in the treatment of diseases.
In future works, we plan to study this biological process
considering nonlinear time and space models to describe
the spatiotemporal evolution patterns of glioma.
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